{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:10:14Z","timestamp":1741237814435,"version":"3.38.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,5]]},"DOI":"10.7759\/cureus.80068","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T08:16:27Z","timestamp":1741162587000},"source":"Crossref","is-referenced-by-count":0,"title":["Role of Chimeric Antigen Receptor T-Cells in the Evolving Therapeutic Landscape of Multiple Myeloma: A Literature Review"],"prefix":"10.7759","author":[{"given":"Marya","family":"Radhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalal A","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghufran M","family":"AlSaffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab  A","family":"Toorani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"ref2","article-title":"Multiple myeloma","author":"Albagoush SA","year":"2019","unstructured":"Albagoush SA, Shumway C, Azevedo AM, et al.. Multiple myeloma. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2019."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman AJ","year":"2010","unstructured":"Waxman AJ, Mink PJ, Devesa SS, et al.. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010, 116:5501-6. 10.1182\/blood-2010-07-298760","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva D","year":"2024","unstructured":"Cortes-Selva D, Perova T, Skerget S, et al.. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024, 144:615-28. 10.1182\/blood.2023022823","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei H","year":"2021","unstructured":"Mei H, Li C, Jiang H, et al.. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021, 14:161. 10.1186\/s13045-021-01170-7","journal-title":"J Hematol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan Z","year":"2019","unstructured":"Yan Z, Cao J, Cheng H, et al.. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019, 6:521-9. 10.1016\/S2352-3026(19)30115-2","journal-title":"Lancet Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2020.07.020","article-title":"Structure-function relationships of chimeric antigen receptors in acute T cell responses to antigen","volume":"126","author":"Xu H","year":"2020","unstructured":"Xu H, Hamburger AE, Mock JY, et al.. Structure-function relationships of chimeric antigen receptors in acute T cell responses to antigen. Mol Immunol. 2020, 126:56-64. 10.1016\/j.molimm.2020.07.020","journal-title":"Mol Immunol"},{"key":"ref8","unstructured":"FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. (2022). Accessed. November 14, 2024: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-ref...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang D","year":"2021","unstructured":"Wang D, Wang J, Hu G, et al.. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood. 2021, 137:2890-901. 10.1182\/blood.2020008936","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi X","year":"2022","unstructured":"Shi X, Yan L, Shang J, et al.. Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol. 2022, 97:537-47. 10.1002\/ajh.26486","journal-title":"Am J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3624","article-title":"Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma","volume":"10","author":"Yan L","year":"2021","unstructured":"Yan L, Qu S, Shang J, et al.. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma. Cancer Med. 2021, 10:563-74. 10.1002\/cam4.3624","journal-title":"Cancer Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Garfall AL","year":"2023","unstructured":"Garfall AL, Cohen AD, Susanibar-Adaniya SP, et al.. Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discov. 2023, 4:118-33. 10.1158\/2643-3230.BCD-22-0074","journal-title":"Blood Cancer Discov"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar SV","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022, 97:1086-107. 10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"ref14","unstructured":"Global Cancer Observatory [Internet]. (2022). Accessed. November 14, 2024: https:\/\/gco.iarc.fr\/en."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2013.35282","article-title":"The morphology of myeloma cells changes with progression of the disease","volume":"17","author":"Wajs J","year":"2013","unstructured":"Wajs J, Sawicki W. The morphology of myeloma cells changes with progression of the disease. Contemp Oncol (Pozn). 2013, 17:272-5. 10.5114\/wo.2013.35282","journal-title":"Contemp Oncol (Pozn)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.346","article-title":"A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li C","year":"2021","unstructured":"Li C, Cao W, Que Y, et al.. A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med. 2021, 11:e346. 10.1002\/ctm2.346","journal-title":"Clin Transl Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren CO","year":"2020","unstructured":"Landgren CO, Chari A, Cohen YC, et al.. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020, 34:1840-52. 10.1038\/s41375-020-0718-z","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12478","article-title":"Clinical course and prognosis of non-secretory multiple myeloma","volume":"95","author":"Chawla SS","year":"2015","unstructured":"Chawla SS, Kumar SK, Dispenzieri A, et al.. Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol. 2015, 95:57-64. 10.1111\/ejh.12478","journal-title":"Eur J Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2015.04.001","article-title":"Plasma cell leukemia: clinicopathologic, immunophenotypic and cytogenetic characteristics of 4 cases","volume":"8","author":"Alghasham N","year":"2015","unstructured":"Alghasham N, Alnounou R, Alzahrani H, Alsharif F. Plasma cell leukemia: clinicopathologic, immunophenotypic and cytogenetic characteristics of 4 cases. Hematol Oncol Stem Cell Ther. 2015, 8:71-7. 10.1016\/j.hemonc.2015.04.001","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref20","unstructured":"Multiple myeloma. diagnosis and treatment. (2017). Accessed: November 14, 2024: https:\/\/www.aafp.org\/pubs\/afp\/issues\/2017\/0315\/p373.html."},{"key":"ref21","unstructured":"International Myeloma Foundation. (1990). Accessed. November 14, 2024: https:\/\/www.myeloma.org\/."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26583","article-title":"CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status","volume":"97","author":"Du J","year":"2022","unstructured":"Du J, Wei R, Jiang S, et al.. CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status. Am J Hematol. 2022, 97:933-41. 10.1002\/ajh.26583","journal-title":"Am J Hematol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld P","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, et al.. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024, 390:301-13. 10.1056\/NEJMoa2312054","journal-title":"N Engl J Med"},{"key":"ref24","unstructured":"DARZALEX \u00ae (daratumumab) injection. (2015). Accessed. November 14, 2024: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX-pi.pdf."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07359.x","article-title":"Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma","volume":"143","author":"Jagannath S","year":"2008","unstructured":"Jagannath S, Barlogie B, Berenson JR, et al.. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008, 143:537-40. 10.1111\/j.1365-2141.2008.07359.x","journal-title":"Br J Haematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao WH","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, et al.. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018, 11:141. 10.1186\/s13045-018-0681-6","journal-title":"J Hematol Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner RG","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, et al.. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022, 603:934-41. 10.1038\/s41586-022-04489-4","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.12170","article-title":"Anti\u2011BCMA CAR\u2011T cell immunotherapy for relapsed or refractory multiple myeloma","volume":"26","author":"Zhang X","year":"2023","unstructured":"Zhang X, Ouyang C, Sun G, Liu H, Qi J, Suo X. Anti\u2011BCMA CAR\u2011T cell immunotherapy for relapsed or refractory multiple myeloma. Exp Ther Med. 2023, 26:471. 10.3892\/etm.2023.12170","journal-title":"Exp Ther Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma","volume":"12","author":"Duan D","year":"2021","unstructured":"Duan D, Wang K, Wei C, et al.. The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma. Front Immunol. 2021, 12:609421. 10.3389\/fimmu.2021.609421","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034629","article-title":"Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)","volume":"10","author":"George P","year":"2020","unstructured":"George P, Dasyam N, Giunti G, et al.. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open. 2020, 10:e034629. 10.1136\/bmjopen-2019-034629","journal-title":"BMJ Open"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial","volume":"41","author":"Xia J","year":"2023","unstructured":"Xia J, Li H, Yan Z, et al.. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023, 41:2583-93. 10.1200\/JCO.22.01824","journal-title":"J Clin Oncol"},{"key":"ref32","unstructured":"Carvykti approval marks second CAR T-cell therapy for multiple myeloma. (2022). Accessed. November 14, 2024: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2022\/fda-carvykti-multiple-myeloma."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje N","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, et al.. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019, 380:1726-37. 10.1056\/NEJMoa1817226","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al.. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021, 384:705-16. 10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger S","year":"2021","unstructured":"Prommersberger S, Reiser M, Beckmann J, et al.. CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. Gene Ther. 2021, 28:560-71. 10.1038\/s41434-021-00254-w","journal-title":"Gene Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03833-6","article-title":"A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count","volume":"20","author":"Wang H","year":"2022","unstructured":"Wang H, Tsao ST, Gu M, et al.. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count. J Transl Med. 2022, 20:608. 10.1186\/s12967-022-03833-6","journal-title":"J Transl Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall AL","year":"2018","unstructured":"Garfall AL, Stadtmauer EA, Hwang WT, et al.. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018, 3:120505. 10.1172\/jci.insight.120505","journal-title":"JCI Insight"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer C","year":"2019","unstructured":"Sommer C, Boldajipour B, Kuo TC, et al.. Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma. Mol Ther. 2019, 27:1126-38. 10.1016\/j.ymthe.2019.04.001","journal-title":"Mol Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel J","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, et al.. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023, 389:335-47. 10.1056\/NEJMoa2303379","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja JG","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al.. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021, 398:314-24. 10.1016\/S0140-6736(21)00933-8","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1953456","article-title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"37","author":"Martin T","year":"2021","unstructured":"Martin T, Usmani SZ, Schecter JM, et al.. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021, 37:1779-88. 10.1080\/03007995.2021.1953456","journal-title":"Curr Med Res Opin"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero P","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al.. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023, 388:1002-14. 10.1056\/NEJMoa2213614","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0080","article-title":"Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting","volume":"13","author":"Alsdorf W","year":"2024","unstructured":"Alsdorf W, Diels J, Ghilotti F, et al.. Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. J Comp Eff Res. 2024, 13:e240080. 10.57264\/cer-2024-0080","journal-title":"J Comp Eff Res"},{"key":"ref44","unstructured":"FDA D.I.S.C.O. Burst Edition. FDA approval of ABECMA (idecabtagene vicleucel) the first FDA approved cell-based gene therapy for the treatment of adult patients with relapsed or refractory multiple myeloma. (2021). Accessed: November 14, 2024: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-abecma-idecabtage...."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-6367(23)00226-9","article-title":"CAR-T prescriber preferences in adolescents and young adults with B-ALL","volume":"15","author":"Godby RC","year":"2022","unstructured":"Godby RC, Ferdjallah A, Alkhateeb HB, et al.. CAR-T prescriber preferences in adolescents and young adults with B-ALL. Blood. 2022, 15:12762-3. 10.1016\/S2666-6367(23)00226-9","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj N","year":"2019","unstructured":"Bouchkouj N, Kasamon YL, de Claro RA, et al.. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res. 2019, 25:1702-8. 10.1158\/1078-0432.CCR-18-2743","journal-title":"Clin Cancer Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"13","author":"Abramson D","year":"2020","unstructured":"Abramson D, Palomba ML, Gordon LI, et al.. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet (London, England). 2020, 13:241. 10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet (London, England)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03538-6","article-title":"Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma","volume":"117","author":"Minakata D","year":"2023","unstructured":"Minakata D, Ishida T, Ando K, et al.. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. Int J Hematol. 2023, 117:729-37. 10.1007\/s12185-023-03538-6","journal-title":"Int J Hematol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.03.003","article-title":"Early chimeric antigen receptor T cell expansion is associated with prolonged progression-free survival for patients with relapsed\/refractory multiple myeloma treated with ide-cel: a retrospective monocentric study","volume":"30","author":"Caillot L","year":"2024","unstructured":"Caillot L, Sleiman E, Lafon I, et al.. Early chimeric antigen receptor T cell expansion is associated with prolonged progression-free survival for patients with relapsed\/refractory multiple myeloma treated with ide-cel: a retrospective monocentric study. Transplant Cell Ther. 2024, 30:630.e1-8. 10.1016\/j.jtct.2024.03.003","journal-title":"Transplant Cell Ther"},{"key":"ref50","unstructured":"A study of LCAR-B38M CAR-T cells, a chimeric antigen receptor T-cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in Chinese participants with relapsed or refractory multiple myeloma (CARTIFAN-1). (2022). Accessed. November 14, 2024: https:\/\/clinicaltrials.gov\/study\/NCT03758417?cond=Multiple%20Myeloma&intr=Car-T%20Cell%20Therapy&page=2&rank=11."},{"key":"ref51","unstructured":"Safety and efficacy of anti-GPRC5D CAR-T cells therapy in the treatment of r\/r MM. (2023). Accessed. November 14, 2024: https:\/\/www.cureus.com\/publish\/articles\/320586-the-role-of-chimeric-antigen-receptor-t-cells-in-the-evolving-therapeu...."},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3674","article-title":"Construction and evaluation of a novel humanized HER2-specific chimeric receptor","volume":"16","author":"Sun M","year":"2014","unstructured":"Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y. Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res. 2014, 16:R61. 10.1186\/bcr3674","journal-title":"Breast Cancer Res"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain","volume":"24","author":"Priceman SJ","year":"2018","unstructured":"Priceman SJ, Tilakawardane D, Jeang B, et al.. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain. Clin Cancer Res. 2018, 24:95-105. 10.1158\/1078-0432.CCR-17-2041","journal-title":"Clin Cancer Res"},{"key":"ref54","unstructured":"DESCAR-T. a French nationwide registry for patients treated by chimeric antigen receptor T (CAR-T) cells. (2018). Accessed: November 14, 2024: https:\/\/www.ipaac.eu\/roadmap\/detail\/50."},{"key":"ref55","unstructured":"CARVYKTI - EMagine\/CARTITUDE-6 (MMY3005) Study. (2024). Accessed. November 14, 2024: https:\/\/www.jnjmedicalconnect.com\/products\/carvykti\/medical-content\/carvykti-emaginecartitude6-mmy3005-study."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.001","article-title":"Cost-effectiveness of anti-BCMA chimeric antigen receptor T cell therapy in relapsed\/refractory multiple myeloma","volume":"30","author":"Yamamoto C","year":"2024","unstructured":"Yamamoto C, Minakata D, Yokoyama D, et al.. Cost-effectiveness of anti-BCMA chimeric antigen receptor T cell therapy in relapsed\/refractory multiple myeloma. Transplant Cell Ther. 2024, 30:118.e1-15. 10.1016\/j.jtct.2023.10.001","journal-title":"Transplant Cell Ther"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107074","article-title":"Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: longitudinal findings from the phase 2 KarMMa trial","volume":"129","author":"Delforge M","year":"2023","unstructured":"Delforge M, Otero PR, Shah N, et al.. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: longitudinal findings from the phase 2 KarMMa trial. Leuk Res. 2023, 129:107074. 10.1016\/j.leukres.2023.107074","journal-title":"Leuk Res"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2207742","article-title":"Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma in China","volume":"26","author":"Wu W","year":"2023","unstructured":"Wu W, Ding S, Mingming Z, et al.. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma in China. J Med Econ. 2023, 26:701-9. 10.1080\/13696998.2023.2207742","journal-title":"J Med Econ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/320586-role-of-chimeric-antigen-receptor-t-cells-in-the-evolving-therapeutic-landscape-of-multiple-myeloma-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T08:16:32Z","timestamp":1741162592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/320586-role-of-chimeric-antigen-receptor-t-cells-in-the-evolving-therapeutic-landscape-of-multiple-myeloma-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":58,"URL":"https:\/\/doi.org\/10.7759\/cureus.80068","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,5]]}}}